The selective serotonin reuptake inhibitor fluoxetine does not change rectal sensitivity and symptoms in patients with irritable bowel syndrome: A double blind, randomized, placebo-controlled study

Kuiken, Sjoerd D.; Tytgat, G. N. J.; Boeckxstaens, Guy E.

doi:10.1053/cgh.2003.50032

Cited by 96 publications

(110 citation statements)

References 0 publications

Supporting

Mentioning

101

Contrasting

Unclassified

Order By: Relevance

“…Fluoxetine. Fluoxetine is a selective serotonin-reuptake inhibitor and was studied in patients with IBS but did not alter the threshold for discomfort/pain during rectal distensions (Kuiken et al, 2003).…”

Section: Wilder-smith Et Al (1998) Pharmacology Of Human Pain Modelsmentioning

confidence: 99%

Human Experimental Pain Models for Assessing the Therapeutic Efficacy of Analgesic Drugs

et al. 2012

View full text Add to dashboard Cite

Section: Wilder-smith Et Al (1998) Pharmacology Of Human Pain Modelsmentioning

confidence: 99%

Human Experimental Pain Models for Assessing the Therapeutic Efficacy of Analgesic Drugs

et al. 2012

View full text Add to dashboard Cite

“…In practice however, once the intra-abdominal pressure had been overcome, there was a steep rise in intra-balloon volume, allowing proper recording of respiratory excursions. The distension protocol consisted of a series of phasic, semirandomly ascending isobaric distensions, of 3 mmHg increment above MDP (3,6,12,9,18,15,24,21, 30 mmHg, etc.). The inflation rate was 38 mL/s and each distension step lasted 2 min, separated by 1-min intervals at baseline (MDP).…”

Section: Barostat Studiesmentioning

confidence: 99%

Relationship between symptoms and hypersensitivity to rectal distension in patients with irritable bowel syndrome

Kuiken¹,

Lindeboom

Tytgat³

et al. 2005

Aliment Pharmacol Ther

View full text Add to dashboard Cite

SUMMARYBackground: Visceral hypersensitivity is considered an important pathophysiological mechanism in irritable bowel syndrome, yet its relationship to symptoms is unclear. Aim: To detect possible associations between symptoms and the presence of hypersensitivity to rectal distension in patients with irritable bowel syndrome. Methods: Ninety-two irritable bowel syndrome patients and 17 healthy volunteers underwent a rectal barostat study. The association between specific irritable bowel syndrome symptoms and the presence of hypersensitivity was examined using Area under the Receiver Operating Characteristic curves. Results: Irritable bowel syndrome patients had significantly lower thresholds for discomfort/pain than healthy volunteers: 24 (18-30) and 30 (27-45) mmHg above minimal distending pressure, respectively. Forty-

show abstract

“…Fluoxetine has been shown to decrease orocecal and whole gut transit times in both constipation-predominant IBS patients and controls (Gorard et al 1994). In another study (Kuiken et al 2003) forty non-depressed IBS patients underwent a rectal barostat study to assess the sensitivity to rectal distention before and after 6 weeks of treatment with fl uoxetine 20 mg or placebo. At baseline, 21 of 40 patients showed hypersensitivity to rectal distention.…”

Section: Selective Serotonin Reuptake Inhibitorsmentioning

confidence: 99%

Serotonin receptor modulators in the treatment of irritable bowel syndrome

Fayyaz

Lackner

2008

TCRM

View full text Add to dashboard Cite

Abstract:The aim of this article is to review the pathophysiology and clinical role of serotonin receptor modulators used in the treatment of irritable bowel syndrome. Serotonin is an important monoamine neurotransmitter that plays a key role in the initiation of peristaltic and secretory refl exes, and in modulation of visceral sensations. Several serotonin receptor subtypes have been characterized, of which 5HT3, 5HT4, and 5HT1b are the most important for GI function. 5HT4 agonists (eg, tegaserod) potentiate peristalsis initiated by 5HT1 receptor stimulation. 5HT4 agonists are therefore useful in constipation predominant form of IBS and in chronic constipation. 5HT3 antagonists (Alosetron and Cilansetron) prevent the activation of 5HT3 receptors on extrinsic afferent neurons and can decrease the visceral pain associated with IBS. These agents also retard small intestinal and colonic transit, and are therefore useful in diarrhea-predominant IBS. Tegaserod has been demonstrated in several randomized, placebo controlled trials to relieve global IBS symptoms as well as individual symptoms of abdominal discomfort, number of bowel movements and stool consistency. Several randomized, controlled trials have shown that alosetron relieves pain, improves bowel function, and provides global symptom improvement in women with diarrhea-predominant irritable bowel syndrome. However, ischemic colitis and severe complications of constipation have been major concerns leading to voluntary withdrawal of Alosetron from the market followed by remarketing with a comprehensive risk management program.

show abstract

The selective serotonin reuptake inhibitor fluoxetine does not change rectal sensitivity and symptoms in patients with irritable bowel syndrome: A double blind, randomized, placebo-controlled study

Abstract: Fluoxetine does not change rectal sensitivity in IBS patients. Possible beneficial effects on pain perception need to be confirmed in larger trials.

Cited by 96 publications

References 0 publications

Human Experimental Pain Models for Assessing the Therapeutic Efficacy of Analgesic Drugs

Human Experimental Pain Models for Assessing the Therapeutic Efficacy of Analgesic Drugs

Relationship between symptoms and hypersensitivity to rectal distension in patients with irritable bowel syndrome

Serotonin receptor modulators in the treatment of irritable bowel syndrome

Contact Info

Product

Resources

About